Portfolio Lab

Nurix Therapeutics, Inc.

  • Stock
  • Ticker NRIX
  • Nasdaq

Health care · Pharmaceuticals · USA

$12.85 −5.51%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Nurix Therapeutics, Inc. since 07/2020, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

NRIXGlobal equities (VT)

$10,000 grew to $3,842. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −91.5% in 10/2023, measured from the peak in 01/2021. The old peak has not been reached again yet.

1-year return
−16.2%
5-year return p.a.
−16.3%
Return p.a. since 07/2020
−6.0%
Volatility p.a.
76.6%
Largest decline
−91.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end11/202402/202505/202508/202511/202502/202605/202608/2026
Income statement
Revenue1318447.9146.39.0673
Operating income-65-63-48-91-83-92-94559
EBITDA-62-61-46-89-81-90-92562
Net income-59-56-43-86-78-87-90550
Earnings per share-0.75-0.67-0.52-1.03-0.83-0.79-0.814.73
Balance sheet
Total assets6696155925226886365361,195
Liabilities142134144150149155133227
Equity527481448372539481403968
Cash1107684782477168720
Cash flow
Operating cash flow-49-61-63-57-68-72-97616
Capital expenditure-2.1-3.5-2.7-2.7-5.1-1.0-1.9-1.4
Free cash flow-51-65-66-60-73-73-99614

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2024 at +82.6%, weakest 2022 at −62.1%. 2 of 5 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
13 Oct 2026$4.73
9 Jul 2026−$0.81
8 Apr 2026−$0.79
28 Jan 2026−$0.83
9 Oct 2025−$1.03
9 Jul 2025−$0.52
8 Apr 2025−$0.67
28 Jan 2025−$0.75
11 Oct 2024−$0.67
11 Jul 2024−$0.71
10 Apr 2024−$0.76
15 Feb 2024−$0.77

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.3bn
Market cap in trading currency
$1.40bn
Enterprise value
$684m
P/E
5.6
P/S
2.00
P/B
1.45
EV/Sales
0.97
EV/EBITDA
2.3
Earnings yield
17.9%
FCF yield
26.3%

Results (last four quarters)

Revenue
$702m
Gross profit
–
EBITDA
$298m
Net income
$295m
Earnings per share
$2.30
Revenue per share
$6.43
Revenue growth
+8,426.3%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
41.3%
Net margin
42.0%
Return on equity
44.0%
Return on assets
24.7%

Balance sheet and cash flow

Cash
$720m
Cash per share
$6.59
Financial debt
–
Debt/equity %
–
Current ratio
8.44
Book value per share
$8.86
Operating cash flow
$379m
Free cash flow
$370m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
109m
Volume
2.43m
Avg. volume 3 months
2.41m
Relative volume
1.0

Price and technicals

Price
$12.85
1 day
−5.5%
52-week high
$27.79
52-week low
$12.85
Distance to 52-week high
−53.8%
Distance to 52-week low
0.0%
Distance to 50-day line
−41.8%
Distance to 200-day line
−35.9%
RSI (14)
21
Volatility 1M
171.9%

Performance

1 week
−17.0%
1 month
−49.6%
3 months
−51.1%
6 months
−26.6%
YTD
−32.3%
1 year
−10.3%

Dates

Fiscal year end
30 Nov 2025
Most recent quarter
31 Aug 2026

Frequently asked questions

How has NRIX performed since 07/2020?

$10,000 grew to $6,760 by 20 Nov 2026, which is −6.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is NRIX?

Volatility was 76.6% per year, measured on monthly returns. The largest decline from a peak was −91.5%, with the low in 10/2023.

How does NRIX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +12.0% per year at 15.1% volatility, NRIX returned −6.0% at 76.6%. The correlation of monthly returns was 0.44; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Nurix Therapeutics, Inc. (NRIX): Return and risk